TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07110337: Diagnosing Epilepsy To EffeCT Change

Sponsor: Epiminder America, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 210 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,987,600

Rescue Site Savings

+$1,978,800

Unlock Full NCT07110337 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07110337 Rescue Dossier →